A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Daily for Four Years to Reduce the Risk of Biopsy-Dectectable Prostate Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Daily for Four Years to Reduce the Risk of Biopsy-Dectectable Prostate Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2017

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Benign prostatic hyperplasia; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REDUCE
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 May 2017 Results evaluating efficacy of dutasteride on nocturia or sleep complaints, presented at the 112th Annual Meeting of the American Urological Association
    • 16 May 2017 Results assessing the effect of sleep disturbances on BPH development and symptom progression, presented at the 112th Annual Meeting of the American Urological Association.
    • 10 May 2016 Retrospective analysis results (n=6422) presented at the 111th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top